Novo Nordisk celebrates 75-year commitment to diabetes research

Novo NordiskNovo Nordisk celebrates two milestone anniversaries, which demonstrates the company's long-term commitment to diabetes care and research. The day marks the 75-year anniversary of the Steno Diabetes Center and the 50-year anniversary of the Hagedorn Research Institute.

Both institutions will open their doors to the public on 5 November with a range of exhibitions, film showings, food tastings and presentations available. Visitors can experience 'looking through the body with laser light', learn which role diet and exercise play in diabetes care or hear a talk about the prospects of finding a cure for the disease.

Steno Diabetes Center and Hagedorn Research Institute are responsible for several groundbreaking research results. Among the most notable achievements is the development of protamine insulin – the world's first long-acting insulin, and its successor, Neutral Protamine Hagedorn (NPH) insulin, a more convenient and versatile product which could be successfully mixed with fast-acting insulin. Both were developed at the then Nordisk Insulinlaboratorium and clinically tested at the Steno facility. NPH is still in use as a long-acting insulin.

Today, the research effort at Steno Diabetes Center focuses on the causes of beta cell death as well as on the treatment and prevention of diabetes complications. Research into the prevention and treatment of type 2 diabetes is also a vital area of investigation. In fact, the Steno approach to diet and control has become a role model for diabetes clinics around the world.

Knut Borch-Johnsen, director, professor at Steno Diabetes Center says: "For Steno Diabetes Center, the ultimate goal is cure and prevention, but until this is reached our focus will continue to be optimal care for patients. We develop programmes and treatment strategies which prevent life-threatening complications and improve the quality of life for all patients with diabetes."

Work at the Hagedorn Research Institute deals mainly with how to replace or preserve the insulin-producing beta cell mass, and stem cell research is an important element of this area. The institute works closely with the Research & Development department at Novo Nordisk on the mutual goal of eventually developing a cure for diabetes.

Ole Dragsbæk Madsen, chief of Research at Hagedorn says: "It is a truly unique constellation of a pharmaceutical company to have an independent basic research institution like Hagedorn Research Institute that is devoted to finding a cure for diabetes. The only question is at what point in the future this will happen."

Steno Diabetes Center and Hagedorn Research Institute are open to the public on 5 November between 13.00 and 15.00.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...